Merck's Nobivac NXT HCPChFeLV Feline Vaccine Receives Positive Recommendation from European CVMP
Introduction of the First Self-Amplifying RNA Vaccine in the Veterinary Field
The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Nobivac NXT HCPChFeLV, a pentavalent feline vaccine developed by Merck's subsidiary, Intervet. This decision marks a historic milestone as it represents the first recommendation for the approval of a vaccine utilizing self-amplifying RNA (saRNA) technology in the veterinary field within the European Union (EU). Unlike conventional mRNA vaccines, saRNA technology enables the vaccine to replicate and amplify the antigen within the body, allowing for a potent immune response with a lower dosage. This low-dose approach aligns well with the needs of the veterinary clinical market, which seeks to minimize stress and adverse reactions associated with vaccinations in companion animals.
Maximized Clinical Convenience through Simultaneous Prevention of Five Pathogens
This vaccine provides protection against five pathogens that threaten feline health: feline herpesvirus-1 (FHV-1), feline calicivirus (FCV), feline panleukopenia virus (FPLV), Chlamydia felis, and feline leukemia virus (FeLV) in a single administration. The first four pathogens are addressed using live-attenuated strains, while the critical FeLV is targeted using saRNA technology in conjunction with a replication-defective viral vector. This recommendation is based on robust data, including 15 laboratory studies and one field trial, demonstrating the safety and efficacy of the vaccine. With only transient swelling or mild fever observed as potential adverse effects, the vaccine is expected to be rapidly adopted in clinical practice.
Reshaping the Global Companion Animal Vaccine Market and Competitive Landscape
The global feline vaccine market is currently valued at approximately USD 1.5 billion and is projected to reach USD 3.1 billion by 2035, with an annual growth rate of 7.6%. Zoetis currently holds the leading market share at 23.5%, followed by Merck and Boehringer Ingelheim, creating a competitive triopoly. In the FeLV prevention market, Boehringer Ingelheim's Purevax and other canarypox vector vaccines have been key competitors. Merck is expected to establish a strong technological barrier and secure a differentiated advantage in the premium market through the launch of its next-generation saRNA-based vaccine.
Strengthening Merck Animal Health's Portfolio and Commercialization Prospects
Merck's animal health division has established itself as a key growth driver, with revenues of USD 6.4 billion in 2025, representing an 8% increase year-over-year. Upon completion of the final approval by the European Commission (EC), Merck is poised to significantly strengthen its vaccine portfolio and expand its market share across Europe. Europe has high rates of companion animal vaccination and a strong willingness to pay for premium products, suggesting a high potential for rapid market penetration of the new vaccine. From an investor perspective, the introduction of high-margin products is expected to improve profitability, while veterinarians can anticipate standardized vaccination protocols and maximized preventive efficacy.
Merck's Nobivac NXT HCPChFeLV has received approval recommendation from the European EMA CVMP based on 15 laboratory studies and one field trial, bringing the world's first veterinary self-amplifying RNA (saRNA) vaccine closer to commercialization. This signifies that Merck has secured a strong technological differentiation in the USD 1.5 billion global feline vaccine market, where Zoetis holds a 23.5% market share and Boehringer Ingelheim is a key competitor. With USD 6.4 billion in revenue in 2025, Merck Animal Health's diversification of its companion animal portfolio and the launch of high-margin new products are expected to lead to improved operating profit margins in the medium to long term, which is a positive signal for investors. For researchers and veterinary clinicians, the availability of an innovative treatment option that utilizes the saRNA platform to reduce vaccination side effects through low-dose administration and prevent five key pathogens with a single formulation has significant clinical value.